Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 18, 1998
Issued Date -
N/A
app pub date -
Feb 9, 1995
filing date -
Jun 16, 1987
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of hormone-dependent tumors, endometriosis or dysmenorrhea.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully